Drug Discovery

Imagine a world where getting vaccinated no longer means facing a needle and syringe, but instead, involves a simple patch applied to the skin. This prospect is rapidly becoming a reality thanks to the innovative work of the University of Queensland (UQ) and Brisbane-based biotech company Vaxxas.

Aneuploidy, the presence of an abnormal number of chromosomes within a cell, is widely recognized as a defining hallmark of cancer. This association has guided cancer diagnostics and research for years, embedding in the scientific community's understanding of how cancers develop and progress.

Glioblastoma multiforme, an aggressive form of brain cancer, has long been a formidable challenge in the medical field. With patient survival rates stagnating around 15 to 18 months, the need for innovative treatment approaches is critical. NeOnc Technologies, under the leadership of Dr. Thomas

The pharmaceutical industry is on the brink of significant transformation, driven by advancements in oncology, artificial intelligence (AI), and evolving policy landscapes. As we look towards 2025 and beyond, these changes promise to revolutionize drug development, clinical trials, and patient

Prostate cancer remains one of the most common cancers among men, and while hormone therapies have significantly improved patient outcomes, resistance to these treatments is a major challenge. The emergence of NXP800, a novel drug currently under clinical trials, offers a promising new approach to

A groundbreaking discovery in cancer research has unveiled a "genetic signature" involving 177 genes that are shared across multiple cancer types, fundamentally challenging prior assumptions about the mechanisms driving cancer metastasis. These findings open new avenues for innovative